BARBARA BUMSTEAD: Open Payments
NPI 1164497236 · BAY SHORE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,189 in 53 payments from 12 companies in 2025. Trend: 2023 $4,781 · 2024 $5,419 · 2025 $7,189
Consulting: $3,488Food & beverage: $2,253Travel & lodging: $1,279Education: $169
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 22 | $5,246 |
| Biogen, Inc. | 10 | $453 |
| ARGENX US, INC. | 6 | $342 |
| Genentech USA, Inc. | 2 | $226 |
| Novartis Pharmaceuticals Corporation | 2 | $201 |
| Teva Pharmaceuticals USA, Inc. | 2 | $169 |
| E.R. Squibb & Sons, L.L.C. | 2 | $146 |
| EMD Serono, Inc. | 1 | $134 |
| Lundbeck LLC | 2 | $124 |
| TG Therapeutics, Inc. | 1 | $79 |
Products named: UPLIZNA, TYSABRI, Ocrevus, KESIMPTA, VYVGART HYTRULO, VYVGART, ZEPOSIA, VYEPTI.
Industry payments across NY — which companies pay providers there.
